Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT836 CAR T-cell Therapy + Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT07221032Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT836 in multiple myeloma (MM) (3 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Incidence of Grade 3 or higher adverse events up to 2 years. Started Aug 2026; status: recruiting.
02
Drugs
FT836
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07221032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221032.